Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,681 to 2,700 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Folic Acid 4 mg vs Placebo: Stillbirth | 15 of 1,364 26 of 1,374 | -0.8 points -1.8 to 0.1 | 2,738 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Eplerenone: Double-blind Phase vs Placebo: Double-blind Phase: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date | 249 of 1,364 356 of 1,373 | -7.7 points -10.8 to -4.6 | 2,737 | NCT00232180 A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines |
| Abiraterone vs Enzalutamide: deaths from any cause | 1,007 of 1,316 1,036 of 1,415 | 3.3 points 0.0 to 6.5 | 2,731 | NCT05968599 A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer |
| Home Monitoring Guided OAC vs Physician-Directed OAC: Rates of All-cause Mortality | 147 of 1,357 140 of 1,361 | 0.5 points -1.8 to 2.9 | 2,718 | NCT00559988 Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk |
| Home Monitoring Guided OAC vs Physician-Directed OAC: Rate of Major Bleeding Events | 46 of 1,357 34 of 1,361 | 0.9 points -0.4 to 2.2 | 2,718 | NCT00559988 Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk |
| Home Monitoring Guided OAC vs Physician-Directed OAC: serious adverse events | 372 of 1,357 374 of 1,361 | -0.1 points -3.4 to 3.3 | 2,718 | NCT00559988 Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk |
| Associated With Rotigotine vs Not Associated With Rotigotine: serious adverse events | 261 of 1,390 269 of 1,328 | -1.5 points -4.5 to 1.5 | 2,718 | NCT00599339 Transdermal Rotigotine User Surveillance Study |
| Single MDA vs Repeated MDA: deaths from any cause | 5 of 1,265 15 of 1,447 | -0.6 points -1.3 to 0.0 | 2,712 | NCT02509481 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study |
| Single MDA vs Repeated MDA: serious adverse events | 10 of 1,265 19 of 1,447 | -0.5 points -1.3 to 0.3 | 2,712 | NCT02509481 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study |
| Arm I:Sentinel Node Resection+Conventional Axillary Dissection vs Arm II: Sentinel Node Resection Followed by Node Examination: Morbidity - Number of Participants With Residual Arm Numbness | 408 of 1,336 103 of 1,371 | 23.0 points 20.2 to 25.9 | 2,707 | NCT00003830 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations, Emergency Department (ED) Visits, Observation Stays, and Deaths | 883 of 1,358 864 of 1,349 | 1.0 points -2.6 to 4.6 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With COPD Exacerbation | 689 of 1,358 706 of 1,349 | -1.6 points -5.4 to 2.2 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Observation Stays | 295 of 1,358 269 of 1,349 | 1.8 points -1.3 to 4.8 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Emergency Department Visits | 702 of 1,358 694 of 1,349 | 0.2 points -3.5 to 4.0 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations | 502 of 1,358 499 of 1,349 | -0.0 points -3.7 to 3.6 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays | 411 of 1,358 398 of 1,349 | 0.8 points -2.7 to 4.2 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Deaths Among Participants | 117 of 1,358 117 of 1,349 | -0.1 points -2.2 to 2.1 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: deaths from any cause | 117 of 1,358 117 of 1,349 | -0.1 points -2.2 to 2.1 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: serious adverse events | 502 of 1,358 499 of 1,349 | -0.0 points -3.7 to 3.6 | 2,707 | NCT02478359 Walk On! Physical Activity Coaching |
| Navigator Arm vs Non-Intervention Arm: Number of Participants Who do Not Receive Diagnostic Audiological Testing (Aim 1) | 378 of 1,601 336 of 1,098 | -7.0 points -10.4 to -3.6 | 2,699 | NCT03875339 Communities Helping the Hearing of Infants by Reaching Parents |
Code
curl "https://conductscience.org/api/comparisons/v1?page=135"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=135
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01355159-8454f45d",
"title": "Folic Acid 4 mg vs Placebo: Stillbirth",
"summary": "15 of 1364 against 26 of 1374; risk difference -0.8 points, 95% interval -1.8 to 0.1; NCT01355159, High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention",
"record": "/library/comparisons/NCT01355159-8454f45d",
"nct_id": "NCT01355159",
"kind": "outcome",
"participants": 2738,
"risk_difference": {
"value": -0.007925785535308004,
"lower": -0.01760378463848837,
"upper": 0.0013307635112100417
},
"group_1": "15 of 1,364",
"group_2": "26 of 1,374",
"difference": "-0.8 points",
"interval": "-1.8 to 0.1",
"trial_title": "High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention"
},
{
"id": "NCT00232180-9e4d5c6a",
"title": "Eplerenone: Double-blind Phase vs Placebo: Double-blind Phase: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date",
"summary": "249 of 1364 against 356 of 1373; risk difference -7.7 points, 95% interval -10.8 to -4.6; NCT00232180, A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines",
"record": "/library/comparisons/NCT00232180-9e4d5c6a",
"nct_id": "NCT00232180",
"kind": "outcome",
"participants": 2737,
"risk_difference": {
"value": -0.07673491487484863,
"lower": -0.1075893893470811,
"upper": -0.0457049385479094
},
"group_1": "249 of 1,364",
"group_2": "356 of 1,373",
"difference": "-7.7 points",
"interval": "-10.8 to -4.6",
"trial_title": "A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=136",
"request_id": "A53hJPnMLgnbdcsa"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant